Cargando…
Osteosarcoma in Korean children and adolescents
Osteosarcoma is the most frequent primary bone tumor. Advances in combination chemotherapy and surgical technique have greatly improved the survival of patients with osteosarcoma. In Korea, improvements in osteosarcoma treatment have been made over the past two decades. The 5-year event-free surviva...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Pediatric Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414626/ https://www.ncbi.nlm.nih.gov/pubmed/25932033 http://dx.doi.org/10.3345/kjp.2015.58.4.123 |
_version_ | 1782368971904778240 |
---|---|
author | Lee, Jun Ah |
author_facet | Lee, Jun Ah |
author_sort | Lee, Jun Ah |
collection | PubMed |
description | Osteosarcoma is the most frequent primary bone tumor. Advances in combination chemotherapy and surgical technique have greatly improved the survival of patients with osteosarcoma. In Korea, improvements in osteosarcoma treatment have been made over the past two decades. The 5-year event-free survival rate of Korean children and adolescents with localized disease is 64.6%, comparable to that of American or European patients. This article provides an overview of current therapies for osteosarcoma in Korea. |
format | Online Article Text |
id | pubmed-4414626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | The Korean Pediatric Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-44146262015-04-30 Osteosarcoma in Korean children and adolescents Lee, Jun Ah Korean J Pediatr Review Article Osteosarcoma is the most frequent primary bone tumor. Advances in combination chemotherapy and surgical technique have greatly improved the survival of patients with osteosarcoma. In Korea, improvements in osteosarcoma treatment have been made over the past two decades. The 5-year event-free survival rate of Korean children and adolescents with localized disease is 64.6%, comparable to that of American or European patients. This article provides an overview of current therapies for osteosarcoma in Korea. The Korean Pediatric Society 2015-04 2015-04-22 /pmc/articles/PMC4414626/ /pubmed/25932033 http://dx.doi.org/10.3345/kjp.2015.58.4.123 Text en Copyright © 2015 by The Korean Pediatric Society http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Lee, Jun Ah Osteosarcoma in Korean children and adolescents |
title | Osteosarcoma in Korean children and adolescents |
title_full | Osteosarcoma in Korean children and adolescents |
title_fullStr | Osteosarcoma in Korean children and adolescents |
title_full_unstemmed | Osteosarcoma in Korean children and adolescents |
title_short | Osteosarcoma in Korean children and adolescents |
title_sort | osteosarcoma in korean children and adolescents |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414626/ https://www.ncbi.nlm.nih.gov/pubmed/25932033 http://dx.doi.org/10.3345/kjp.2015.58.4.123 |
work_keys_str_mv | AT leejunah osteosarcomainkoreanchildrenandadolescents |